Contents

Welcome
IXTH INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS
Miklos Bely and David Apathy

Preface
IXTH INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS
HISTORY OF INTERNATIONAL SYMPOSIA ON AMYLOIDOSIS
Alan S. Cohen

Introductory Lectures

0.1. AMYLOIDOSIS: THE LAST THREE CENTURIES
Robert A. Kyle

0.2. HISTORY OF THE AMYLOID FIBRIL, AMYLOID SYMPOSIA AND AMYLOID JOURNAL
Jean D. Sipe and Alan S. Cohen

1. Basic Science Symposia

Keynote Lecture: 1.1.

RAGE AND AMYLOIDOSES
Jin Yu, Hong Zhu, Shi Du Yan, Ann Marie Schmidt, David Stern and Mark Kindy

1.1.1. Poster and Oral Presentation
KIDNEY DIALYSIS-ASSOCIATED AMYLOIDOSIS: A MOLECULAR ROLE FOR Divalent Ion in Fiber Formation
Andrew Miranker

1.1.2. Poster and Oral Presentation
STRUCTURE, FOLDING AND FIBRILLOGENESIS OF β2-MICROGLOBULIN AND ITS MAIN FIBRILLOGENIC TRUNCATED FORM

1.1.3. Poster and Oral Presentation
AMYLOID-LIKE FIBRILS FORM FROM MORE THAN ONE PEPTIDE DOMAIN OF HUMAN AND RAT ISLET AMYLOID POLYPEPTIDE
Emma T. A. S. Jaikaran, Michael Grob, Jesus Zurdo, Louise Serpell, Paul E. Fraser and Anne Clark

1.1.4. Poster and Oral Presentation
WHAT IS AN "AMYLOIDOGENIC" SEQUENCE?
Melanie R. Nilsson and Christopher M. Dobson

1.1.5. Poster and Oral Presentation
AB1-40 ASSEMBLY INTO FIBRILS INVOLVES MULTIPLE PATHWAYS: IMPLICATIONS FOR INHIBITION STRATEGIES
Claire Goldsbury, Ueli Aebi and Peter Frey
IXth International Symposium on Amyloidosis
July 15-21, 2001 Budapest, Hungary
Contents

1.1.6. Poster and Oral Presentation
CHEMICAL ANALYSIS OF PRIONS
Thomas R. Appel 34

1.1.7. Poster Only
DYNAMICS OF TTR FIBRILS ASSEMBLY: LEUSSPRO FIBRILS FORMED AT PHYSIOLOGICAL PH VERSUS WT FIBRILS PRODUCED BY ACIDIFICATION
Isabel Cardoso, Claire Goldsbury, Ueli Aebi and Marla João Saraiva 37

1.1.8. Poster Only
INVESTIGATING THE EARLY STEPS IN HUMAN AMYLIN FIBRIL FORMATION
Janelle Green, Ueli Aebi, Joerg Kissler, Garth Cooper and Claire Goldsbury 40

Keynote Lecture: 1.2.

SERUM AMYLOID A: HAS IT A FUNCTIONAL ROLE?
Patricia Woo 43

1.2.1. Poster and Oral Presentation
EXPRESSION OF SERUM AMYLOID A IN NORMAL AND MALIGNANT HUMAN TISSUES: IMPLICATIONS FOR ITS LOCAL FUNCTIONS
S. Urreti-Shoval, R.P. Linke and Y. Matzner 44

1.2.2. Poster and Oral Presentation
IMPAIRED CAPACITY OF SERUM AMYLOID A(SAA)-ENRICHED ACUTE-PHASE HIGH-DENSITY LIPOPROTEIN TO DELIVER CHOLESTERYL ESTER TO HUMAN HEPATOMA CELLS. A POSSIBLE ROLE OF SCAVENGER RECEPTOR CLASS B, TYPE I?
A. Artl, G. Marsche, P. Pussinen, G. Knipping, W. Sattler and E. Malle 47

1.2.3. Poster Only
TECHNICAL IMPROVEMENTS FOR THE ANALYSIS OF LIPIDS IN AMYLOID

1.2.4. Poster Only
SERUM AMYLOID A AND SOME CYTOKINES IN PATIENTS WITH PRIMARY (AL), SECONDARY (AA) AND DIALYSIS-RELATED (AβM) AMYLOIDOSIS
R. Ryšále, M. Merta, V. Tesař, T. Zima, J. Lachmanová and S. Sulková 51

1.2.5. Poster Only
THE PHYSIOLOGICAL ROLE OF SERUM AMYLOID A 2.1
Shui-Pang Tam, Alana Flexman and Robert Kisslevsky 54

1.2.6. Poster Only
TRANSMISSION OF MOUSE SENILE AMYLOIDOSIS
Yanming Xing, Xiaoying Fu, Tatsumi Korenaga, Akihiro Nakamura, Takuya Chiba, Kuniko Kogishi, Takatoshi Matsushita, Li Fu, Zhanjun Guo, Masanori Hosokawa, Masayuki Mori and Keiichi Higuchi 57

Keynote Lecture: 1.3.

SERUM AMYLOID P COMPONENT: NORMAL FUNCTIONS AND ROLE IN PATHOGENESIS, DIAGNOSIS AND TREATMENT OF AMYLOIDOSIS
Pepys, M.B. 60

1.3.1. Poster Only
PROTEIN FOLDING ASPECTS OF AMYLOID FIBRIL FORMATION
Marcus Fändrich, Vincent Forge, Matthew A. Fletcher and Christopher M. Dobson 64

II
IXth International Symposium on Amyloidosis
July 15-21, 2001 Budapest, Hungary

Contents

1.2.2. Poster Only
AA AMYLOID DEPOSITION IS COMPLEMENT INDEPENDENT
W.L. Hutchinson, J. Herbert, M. Berto, M.J. Walport and M.B. Pepys

1.3.3. Poster Only
THE SECOND PHASE OF MURINE AMYLOIODGENESIS IS SUPPRESSED BY COLCHICINE
Shmuel Shiraasburg, Mordechai Fren, Yisrael Gal and Avi Livne

2. Lipoproteins and Amyloidosis

Keynote Lecture 2.1.

THE APOLIPOPROTEIN AMYLOIDOSIS
Merrill D. Benson

2.1.1. Poster and Oral Presentation
SAA-ONLY HDL: FORMATION WITH OR WITHOUT THE ACUTE PHASE RESPONSE AND BINDING TO PROTEOGLYCANS
Veneracion G. Cabana, Katherine Olin, Catherine A. Reardon, Ning Feng, Alan Chait and Godfrey S. Getz

2.1.2. Poster and Oral Presentation
MOLEULAR CHARACTERISATION OF HEREDITARY SYSTEMIC AMYLOIDOSIS IN ITALY: IDENTIFICATION OF A NOVEL APOLIPOPROTEIN A1 VARIANT WITH PREDOMINANTLY HEPATIC PHENOTYPY
Laura Olivi, Giovanni Palladini, Vittorio Perfetti, Sabrina Marciano, Maurizio Bruno, Sofia Giorgi, Vittorio Bellotti, Elio A. Bistoni and Giampaolo Merlini

2.1.3. Poster and Oral Presentation
RENAL AMYLOIDOSIS CAUSED BY A NOVEL STOP-CODON MUTATION IN THE APOLIPOPROTEIN A2 GENE
Masahide Yasuki, Juris J. Liepina, Taro Yamashita, Brian Guenther, Martha Skinner, Merrill D Benson

2.1.4. Poster Only
APOLIPOPROTEIN A-IV CO-DEPOSITED WITH TRANSTHYRETIN IN SENILE SYSTEMIC AMYLOIDOSIS
Joakim Berg roten, Charles L. Murphy, Manfred Eulitz, Deborah T. Weiss, Gunilla T. West ermark, Alan Solomon and Per Westermark

2.1.5. Poster Only
APOLIPOPROTEIN E PHENOTYPES IN RHEUMATOID ARTHRITIS WITH OR WITHOUT AMYLOIDOSIS
C.P.J. Muir, M. Lijestrom, S. Titinen, K. Laiho, K. Kuusela and C. Ehnholm

2.1.6. Poster Only
APOLIPOPROTEIN E INHIBITS THE DEPOLYMERIZATION OF β2-MICROGLOBULIN-RELATED AMYLOID FIBRILS AT A NEUTRAL pH
Iru Yamaguchi, Katsuhiko Hisagawa, Naoki Takahashi, Fumitake Gejyo and Hiroosu Naiki

Keynote Lecture 2.2.

SERUM AMYLOID A, IN THE ABSENCE OF HIGH DENSITY LIPOPROTEIN, MODULATES CHOLESTEROL TRANSPORT AND SYNTHESIS: IMPLICATIONS FOR AMYLOID A FIBRIL FORMATION
Jean D. Sipe and Barbara M. Schreibter
IXth International Symposium on Amyloidosis
July 15-21, 2001 Budapest, Hungary

Contents

3. Systemic AA Amyloidosis

Keynote Lecture: 3.1.

AA AMYLOIDOSIS
A PROGRESS REPORT AND POSSIBLE FUTURE DIRECTIONS
Robert Kisilevsky and John B. Aanesin

3.1.1. Poster and Oral Presentation
SAA IS PROCESSED INTRACELLULARLY BY MACROPHAGES PRIOR TO DEPOSITION AS AMYLOID
Barbara Klueve-Beckerman, John Manaloof, Juris J. Liepins and Merrill D. Benson

3.1.2. Poster and Oral Presentation
INVESTIGATION OF THE SERUM AMYLOID A BINDING SITE(S) ON HEPARIN/HEPARAN SULFATE
J.B. Aanesin and R. Kisilevsky

3.1.3. Poster and Oral Presentation
CONTRIBUTION OF GENOTYPES AT THE SAA1 LOCUS TO AMYLOIDOSIS AND DISEASE SEVERITY IN PATIENTS WITH FAMILIAL MEDITERANEAN FEVER
Ruth Gershoni-Baruch, Riva Brik, Marwan Shinawi and Avi Livneh

3.1.4. Poster and Oral Presentation
A NOVEL MUTATION (R92Q) IN THE GENE ENCODING TUMOR NECROSIS FACTOR RECEPTOR 1 IN A DUTCH PATIENT WITH AUTOSOMAL DOMINANT RECURRENT FEVER AND AA AMYLOIDOSIS
Bouke P.C. Hazenberg, Catherine Dodé, Sytze Meijer, Marc Delpech, Joost P.H. Drenth, Pieter L. Jager, Gilles Graeule, Johan Bijzet, Pieter C. Limburg and Martin H. van Rijswijk

3.1.5. Poster and Oral Presentation
SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF FIBRILEX™ (ANTI-AA AMYLOID AGENT) IN HEALTHY AND RENAL IMPAIRED SUBJECTS
Denis Gueronu, Covadonga Garbiando and Julie Launay

3.1.6. Poster Only
SERUM AMYLOID A HAS TWO HEPARIN/HEPARAN SULFATE BINDING SITES
J.B. Aanesin, E. Eilmeva and R. Kisilevsky

3.1.7. Poster Only
THE INFLUENCE OF AGE, SEX, ONSET AND DURATION OF DISEASE ON (AA) AMYLOIDOSIS - A RETROSPECTIVE STUDY
Agnes Apáthy and Miklós Bely

3.1.8. Poster Only
NOVEL POLYMORPHISMS IN THE 5'-FLANKING REGION OF THE HUMAN SERUM AMYLOID A1 (SAA1) GENE AND AN ASSOCIATION WITH REACTIVE AA-AMYLOIDOSIS
Satoshi Baba, Hidenori Nakai, Tadashi Nakamura, Shigeoito Miyamoto, Yasuhiro Oht, Toshie Takahashi, Takeshi Kambara and Yoshihito Tsutsui
IXth International Symposium on Amyloidosis
July 15-21, 2001 Budapest, Hungary
Contents

3.1.9. Poster Only
DYNAMIC OF THE DEVELOPMENT OF SECONDARY AMYLOIDOSIS THROUGHOUT 15 YEARS OF RETROSPECTIVE STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS
V. Grazieni and D. Povilienëte 128

3.1.10. Poster Only
ANALYSIS OF SAA isoFORM MEssER men RNA EXPRESSION AND INHIBITORY EFFECT OF HUMANIZED ANTi-IL-6 RECEPTOR ANTIBODY BY REAL TIME QUANTITATIVE RT-PCR
Keisuke Hagiwara, Elko Nakahara, Masumihi Sugimoto, Yasuhiro Suganuma, Norshiro Nishimoto and Kazuyuki Yoshihaki 131

3.1.11. Poster Only
CAN SAA LEVELS PREDICT RENAL DETERIORATION IN AMYLOIDOSIS SECONDARY TO RHEUMATIC DISEASE?
John A. Hunter, E. Fiona Wood, David Shapiro, Tom Blyth and Margaret Mary Gordon 134

3.1.12. Poster Only
RHEUMATOID ARTHRITIS WITH SECUNDAER AMYLOIDOSIS – A CLINICOPATHOLOGICAL STUDY
E. Matyasovszky, E. Koo, M. Beyi and K. Naidor 136

3.1.13. Poster Only
RAISED CIRCULATING INTERLEUKIN-18 LEVELS IN REACTIVE AA-AMYLOIDOSIS
C.P.J. Maury, S. Tittinen, K. Laiho, K. Kuurela and M. Liljeström 139

3.1.14. Poster Only
SECONDARY AMYLOIDOSIS IN DIFFERENT GROUPS OF IMMUNOMODULATORY TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
D. Povilienëte, V. Grazieni and A. Venalis 141

3.1.15. Poster Only
ADVANCED GLYCA TION END PRODUCTS IN AA AMYLOIDOSIS
Christoph Röcken, Mona Schwan, John Raynes, Barbara Stix and Wolfgang Saeger 144

3.1.16. Poster Only
PREVENTION OF AA AMYLOIDOSIS BY ACTIVE IMMUNOTHERAPY
Maria Schell, Jonathan Wall, Sally Macy, Craig Wooliver, Dennis Wolfenbarger, Robert Donnell, Deborah Weiss and Alan Solomon 146

3.1.17. Poster Only
AN ANCILLARY TOOL FOR THE DIAGNOSIS OF ANIMAL AA AMYLOIDOSIS
Samuel Shnarsburg, Rivka Gali, Samuel Peri, Romelia Koren, Morechau Pras and Avi Livneh 149

3.1.18. Poster Only
DEGRADATION OF SAA AND AA AMYLOID FIBRIL PROTEINS BY MATRIX METALLOPROTEINASES
B. Stix, T. Kallaus, K. Sletten, J. Raynes and C. Röcken 152

3.1.19. Poster Only
SYSTEMIC SECONDARY AMYLOIDOSIS IN PSORIATIC ARTHRITIS.
CASE REPORT AND REVIEW OF THE LITERATURE
Irena Ujfalussy, Nikolay Bely, Eva Koo and Magdalena Senetik 154

3.1.20. Poster Only
TREATMENT OF AMYLOIDOSIS USING AN ANTI-FIBRIL MONOCLONAL ANTIBODY: PRE-CLINICAL EFFICACY IN A MURINE MODEL OF AA-AMYLOIDOSIS
Jonathan Wall, Maria Schell, Rudi Hricic, Sally Macy, Craig Wooliver, Dennis Wolfenbarger, Charles Murphy, Robert Donnell, Deborah T. Weiss and Alan Solomon 158
3.1.21. Poster Only
KINETICS OF PROTEOGLYCANS AND GLYCOSAMINOGLYCANS IN AA AMYLOIDOSIS
Tale N. Wena, Randi Surby, Lone A. Omvedt, Thor Landsverk and Gunnar Husby
161

3.1.22. Poster Only
FIBRATE INHIBITS REACTIVE AA-AMYLOIDOSIS IN MICE.
Toshiyuki Yamada, Takehiro Murai, Tadamiya Hanyu and Takashi Miida
163

3.1.23. Poster Only
AA AMYLOIDOSIS IN TUMOUR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC
SYNDROME
T. Pettersson, L. Kärenkö, H. Nevala, S. Stjernberg, M. Rantakaijarvi, H. Saariluoto, J. Rautu, P. Petersson, M. F.
McDermott and A. Ranki
165

3.1.24. Poster Only
AA AMYLOIDOSIS WITHOUT DEFINABLE UNDERLYING DISEASE
O. Knut, T. Pettersson, T. Törnroth and C.P.J. Maury
168

4. Systemic Primary Amyloidosis

Keynote Lecture: 4.1.

PRIMARY (AL) AMYLOIDOSIS
Giampaolo Merlini, Vittorio Bellotti, Giovanni Palladini, Simona Casarin, Ernesto Aresi, Laura Obici and
Vittorio Perfetti
171

4.1.1. Poster and Oral Presentation
V1. GENE USAGE IN PRIMARY AMYLOIDOSIS
180

4.1.2. Poster and Oral Presentation
PREFERENTIAL ASSOCIATION OF THE 24H FAMILY GERMINE GENE SEGMENT 3R WITH
PRIMARY AMYLOIDOSIS (AL)
Vittorio Perfetti, Simona Casarin, Maurizio Colli Vignarelli, Giovanni Palladini, Edoardo Ascari and
Giampaolo Merlini
183

4.1.3. Poster and Oral Presentation
ESTABLISHMENT OF A FIRST-ORDER KINETIC MODEL OF LIGHT CHAIN AMYLOID FIBRIL
EXTENSION IN VITRO
Noko Takahashi, Kazuhiro Hasegawa, Itaru Yamaguchi, Hiromi Okada, Takanori Ueda, Fumioke Geijo and
Hironobu Naito
186

4.1.4. Poster and Oral Presentation
HEART RATE VARIABILITY ANALYSIS IN AL AMYLOIDOSIS: EVIDENCE FOR PROFOUND
AUTONOMIC DYSFUNCTION
Rodney H. Falk and Brian G. Norwood
189

4.1.5. Poster and Oral Presentation
LOW DOSE CONTINUOUS ORAL MELPHALAN FOR THE TREATMENT OF AL AMYLOIDOSIS
V. Sanchorawala, D.G. Wright, D.C. Seldin, L. Muir, R.H. Falk, K. Finn and M. Skinner
190

4.1.6. Poster and Oral Presentation
HIGH DOSE INTRAVENOUS MELPHALAN AND AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR THE TREATMENT OF AL AMYLOIDOSIS: MORBIDITY AND
MORTALITY
D.G. Wright, V. Sanchorawala, J. Taper, D.C. Seldin, R.H. Falk, L. Demmer, J. Berk, K. Finn, K. Quillen and M.
Skinner
193
Contents

4.1.7. Poster and Oral Presentation
STEM CELL TRANSPLANTATION FOR MANAGEMENT OF PRIMARY SYSTEMIC AMYLOIDOSIS
196

4.1.8. Poster Only
DETECTION AND CHARACTERIZATION OF POST-TRANSLATIONAL MODIFICATIONS IN AMYLOIDOGENIC KAPPA I LIGHT CHAIN PROTEINS BY MASS SPECTROMETRIC PEPTIDE MAPPING
Amaloth Lim, Jeremy Wally, Mary T. Walsh, Martha Skinner and Catherine E. Costello
199

4.1.9. Poster Only
PRIMARY SYSTEMIC AMYLOIDOSIS WITH PREDOMINANT SKELETAL INVOLVEMENT
G. Műzes, P. Nagy, A. Folyovich, D. Gerő, M. Bély and B. Szende
202

4.1.10. Poster Only
LOCALIZED AMYLOIDOMA OF THE RIGHT BRACHIAL PLEXUS
Fabrizio Salvi, Federico Roncaroli, Alessandro Consales, Luca Di Tomaso, Massimo Poppo, Daniele Fultrano and Massimo Siampon
205

4.1.11. Poster Only
PRIMARY AMYLOID ARthropathy versus RHEUMATOID ARTHRITIS - DIFFICULT TO DIFFERENTIATE
Zsuzsa Schmidt, Miklós Bély, Pal N. Kaposi and Ágnes Megyeri
207

4.1.12. Poster Only
COEXISTENT AL AMYLOIDOSIS AND RHEUMATOID ARTHRITIS: A CASE REPORT
T. Szemjébi Szabó and M. Bély
211

4.1.13. Poster Only
EXTRAMEDULLARY SOLITARY PLASMACYTOMA OF NASOPHARYNX WITH PRIMARY AMYLOIDOSIS: A CASE REPORT
214

Keynote Lecture: 4.2.

AL AMYLOIDOSIS: CURRENT DIAGNOSTIC AND THERAPEUTIC ASPECTS
Robert A. Kyle
217

4.2.1. Poster and Oral Presentation
AL AMYLOIDOSIS: SEVERITY OF ILLNESS, TREATMENT DECISIONS AND OUTCOME IN 554 PATIENTS
221

4.2.2. Poster and Oral Presentation
ELIGIBILITY FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY SYSTEMIC AMYLOIDOSIS IS A FAVORABLE PROGNOSTIC FACTOR FOR SURVIVAL
A. Dispenzieri, RA Kyle, M.Q. Lacy, PR Greipp, T Witzig, JA Lust, R Fonseca, SV. Rajkumar, D Larson, TA Theronau and MA Gertz
224

4.2.3. Poster and Oral Presentation
HIGHLY SENSITIVE AUTOMATED IMMUNOASSAY FOR FREE IMMUNOGLOBULIN LIGHT-CHAIN IN DIAGNOSIS AND FOLLOW UP OF AL AMYLOIDOSIS
P.N. Hawkins, R. Gallimore, L. Smith, A.R. Bradwell and H.J. Lachmann
227

VII
Contents

4.2.4. Poster and Oral Presentation
UTILITY OF SERUM FREE LIGHT CHAIN MEASUREMENTS FOR ASSESSING RESPONSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS (AL)
R.S. Abraham, J.A. Katzmann, R.J. Clark, R.A. Kyle and M.A. Gertz

228

4.2.5. Poster and Oral Presentation
VACCINE BASED THERAPY FOR PRIMARY (AL) AMYLOIDOSIS
Rudi Hrmic, Dennis Wolfenbarger, Sallie Macy, Craig Wooliver, Charles Murphy, Maria Schell, Kristal Weaver, Teresa K. Williams, Deborah T. Weiss, Jonathan Wall and Alon Solotenn

234

4.2.7. Poster Only
PREDICTIVE FACTORS FOR THE DIAGNOSIS OF SYSTEMIC AMYLOIDOSIS
Kenneth I. Calanna, Tricia R. Andrews and David M. Menke

236

4.2.8. Poster Only
ULTRASOUND SCAN FINDINGS IN AL AMYLOIDOSIS

239

4.2.9. Poster Only
SPLENECTOMY FOR AMYLOIDOSIS ASSOCIATED FACTOR V DEFICIENCY: LONG-LASTING BENEFIT
P.R. Greipp, L.F. Porrata, C.C. Hook, J.O. Bullard and D.M. Nagorney

242

4.2.10. Poster Only
PATIENTS WITH AL AMYLOIDOSIS TREATED WITH VAD FOLLOWED BY HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION
Ingrid I. van Gemenen, Bouke P.C. Hazenberg, Pieter L. Jager, Jan W. Smit and Edo Vellenga

245

4.2.11. Poster Only
EPIDURAL AMYLOIDOSIS: A RARE CAUSE OF PARAPLEGIA IN MULTIPLE MYELOMA

248

4.2.12. Poster Only
AL AMYLOIDOSIS: THE EXPERIENCE OF THE ITALIAN GROUP

249

4.2.13. Poster Only
CIRCULATING PERIPHERAL BLOOD PLASMA CELLS AS A PROGNOSTIC INDICATOR IN PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS
Animesh Pardasani, S. Vincent Rajkumar, Edwin C. McElroy, Rafael Fosecoa, Angela Dispenczici, Martha Q. Locy, John A. Lust, Robert A. Kyle, Philip R. Greipp, Morrie A. Gertz and Thomas E. Witzig

252

4.2.14. Poster Only
BONE MARROW BIOPSY FINDINGS IN AL AMYLOIDOSIS FOLLOWING TREATMENT WITH HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL SUPPORT: CORRELATION WITH IMMUNOFIXATION ELECTROPHORESIS
N. Swan, E. Mulcahy, B.J. Magnani, M. Skinner and C.J. O'Hara

253
Keynote Lecture: 4.3.

PRIMARY (AL) AMYLOIDOSIS: RECENT DISCOVERIES REGARDING PATHOGENESIS, DIAGNOSIS, AND TREATMENT
A. Solomon, D.T. Weiss and J. Wall 256

4.3.1. Poster and Oral Presentation
DENDRITIC CELL-BASED IDIOTYPE VACCINATION FOR PRIMARY SYSTEMIC AMYLOIDOSIS

4.3.2. Poster and Oral Presentation
PHENOTYPIC TRANSFORMATION OF MESANGIAL CELLS PRECEDES AND IS REQUIRED FOR AL-AMYLOIDOSIS
Guillermo A. Herrera, William J. Russell and James Cardelli 267

4.3.3. Poster and Oral Presentation
THE TROPISM OF ORGAN INVOLVEMENT IN PRIMARY SYSTEMIC AMYLOIDOSIS: CONTRIBUTIONS OF Ig V_L GERMLINE GENE USE AND CLONAL PLASMA CELL BURDEN
R.L. Comenzo, Y. Zhang, C. Martinez, K. Osman and G.A. Herrera 272

4.3.4. Poster Only
TRANSLOCATIONS INVOLVING THE IgH LOCUS ARE EARLY GENETIC EVENTS IN THE CLONAL PLASMA CELLS OF PRIMARY SYSTEMIC AMYLOIDOSIS

4.3.5. Poster Only
LOCALIZATION OF COAGULATION FACTOR X IN AL AND AA AMYLOID
Denise Müller, Christoph Roeken and Alan Solomon 279

4.3.6. Poster Only
ANALYSIS OF IMMUNOGLOBULIN LIGHT CHAINS IN PRIMARY AMYLOIDOSIS—DIRECT ON-LINE ASSAY FOR AMYLOIDOCENIC KAPPA AND LAMBDA LIGHT CHAINS DIRECTLY FROM SERUM

4.3.7. Poster Only
CLINICAL IMPORTANCE OF SERUM AND URINE FREE KAPPA & LAMBDA LIGHT CHAIN CONCENTRATIONS IN PRIMARY (AL) AMYLOIDOSIS
Lian X. Tang, Denny Wolferbergen, Teresa Williams, Deborah T. Weiss and Alan Solomon 284

Keynote Lecture: 4.4.

PROTEIN DEPOSITION DISEASES: WHEN STRUCTURALLY ALTERED PROTEINS ASSEMBLE OUT OF PLACE
Gunnar Husby, Per Brandzaeg, Ove J. Melbye, Keith Thompson and Knut Sletten 287

4.4.1. Poster Only
ARTICULAR MONOClonAL IMMUNOGLOBULIN DEPOSITION DISEASE (MIDD): THREE ILLUSTRATIVE CASES
Gunnar Husby, Harald Aarset, Per Brandzaeg, Ove J. Melbye, Keith Thompson and Knut Sletten 292

IXth International Symposium on Amyloidosis
July 15-21, 2001 Budapest, Hungary
Contents
5-6. Systemic Hereditary Amyloidosis

Keynote Lecture: 5.1.1.

THE TRANSTHYRETIN AMYLOIDOSIS: WHAT WE KNOW AND DON'T KNOW
Jocelyn N. Buxbaum, Rahul Bhatia, Clement Tagoe and Gloria Gallo

5.1.2. Poster and Oral Presentation

EVIDENCE FOR INTRACELLULAR TRANSTHYRETIN AMYLOID FORMATION
Joleen T. White, Traci C. Walkup, Sandra L. Schmid and Jeffery W. Kelly

5.1.3. Poster Only

K69R, A MEVF MUTATION IN A SPANISH PATIENT SUFFERING FMF WITH SEVERE RENAL AMYLOIDOSIS
Anna Aldea, Joan Bauda, Antoni Gayo and Jordi Yagüe

5.1.4. Poster Only

CHARACTERIZATION AND MANAGEMENT OF ANEMIA IN FAMILIAL AMYLOID POLYNEUROPATHY TTR V30M (FAP-I)
I. Beirão, L. Lobato, M. Ramallo, M. Silva, Santos MJ and Guimarães S

5.1.5. Poster Only

A RAPID ON-LINE ASSAY FOR CLINICAL DIAGNOSIS OF AMYLOIDOGENIC TRANSTHYRETIN VARIANTS DIRECTLY FROM SERUM
H. Robert Bergen III, Steven R. Zeldenrust and Stephen Naylor

5.1.6. Poster Only

ORTHOTOPIC LIVER TRANSPLANTATION IN FAMILIAL TRANSTHYRETIN AMYLOIDOSIS: CLINICAL AND NEUROPHYSIOLOGICAL EFFECTS
E. Freund, M. Golling, F. Willig, R. Singer, J. Wührle, R. P. Linke, K. Altland and E. Klar

5.1.7. Poster Only

HOW COUNSELING CARRIERS OF TRANSTHYRETIN V30M MET AMYLOIDOSIS AND END-STAGE RENAL DISEASE IN THE FAMILY?
Luís Lobato, Idália Beirão, Manuela Silva, Jorge Sequeiros and Alda Sousa

5.1.8. Poster Only

INTERCURRENT DISEASES IN FAMILIAL AMYLOID POLYNEUROPATHY TTR V30M (FAP-I)
M. Ramallo, I. Beirão, L. Lobato, M. Silva and S. Guimarães

5.1.9. Poster Only

EARLY ONSET OF AGGRESSIVE FAMILIAL AMYLOIDOTIC POLYNEUROPATHY. REPORT OF A FAMILY WITH RECURRENCE OF TTR ARG 47
P. Salvi, D. Fultron, A. Ferini, A. Tavoni and C.A. Tassinari

5.1.10. Poster Only

A NEW MEVF MUTATION, H475Y, CAUSE SEVERE RENAL AMYLOIDOSIS AND IS DOMINANTLY INHERITED IN A SPANISH FAMILY
Jordi Yagüe, Anna Aldea and Josep M. Campistol

Keynote Lecture 5.2.

LATE-ONSET TRANSTHYRETIN-ASSOCIATED CARDIAC AMYLOIDOSIS
Daniel R. Jacobson

316
CHARACTERIZATION OF MODIFIED SERUM TRANSTHYRETIN
Manahiko Kishikawa, Toyofumi Nakamichi and Akira Shimizu

Keynote Lecture: 5.3.

MAJOR TRENDS IN TRANSTHYRETIN AMYLOIDOSIS RESEARCH
Maria João Mascarenhas Saraiva

BINDING OF TRANSTHYRETIN IN CELL MEMBRANE IN VITRO AND IN VIVO
Taro Yamashita, Barbara Klve-Brechtman, Kenji Ogawa, John Manaloos, Masahide Yezaki, Juris Liepins and Merrill D. Benson

IDENTIFICATION OF NOVEL TRANSTHYRETIN VARIANTS IN FAMILIAL TRANSTHYRETIN AMYLOIDOSIS BY MASS SPECTROMETRIC PEPTIDE MAPPING AND DNA SEQUENCE ANALYSIS
Catherine E. Costello, Amarendra Lim, Tatiana Prokacova, Mark E. McComb, Peter B. O’Connor, Lawreen H. Connors and Martha Skinner

STRUCTURE OF TTR R104H: A NON-AMYLOIDGENIC VARIANT WITH PROTECTIVE CLINICAL EFFECTS
S. Macedo-Ribeiro, M. Coll, M.J.M. Saraiva and A.M. Damas

PARTIAL UNFOLDING OF THE NON-NATIVE MONOMER IS THE KEY EVENT IN TRANSTHYRETIN AMYLOIDOSIS
Alexandre Quintas, Daniela C. Vaz, Maria João M. Saraiva and Rui M. M. Brito

THREE-DIMENSIONAL ANALYSES OF AMYLOID DEPOSITS ON PERIPHERAL NERVES IN FAP PATIENTS, WITH SPECIAL REFERENCE TO THE EFFECT OF LIVER TRANSPLANTATION
Takashi Hattori, Yu-toki Takai and Shu-chi Ikeda

PRESENCE OF AUTOANTIBODY AGAINST ATTR V30M AFTER SEQUENTIAL LIVER TRANSPLANTATION
Hisayasu Terao, Yukio Ando, Takahiro Tajiri, Katsuki Haraoka, Masaaki Nakamura, Kenen Ohbayashi, Shogo Minami, Shozo Shoji, Kazako Hata, Kazuko Nakagawa, Takashi Ishizaki, Hiroaki Okabe, Shunji Uemoto, Koichi Tanaka and Yukihiko Inoue

VITREOUS AMYLOID IS FORMED BY TRANSTHYRETIN (TTR) FROM THE RETINA IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP)
Yukio Ando, Eiko Ando, Katsuki Haraoka, Mikiko Fukushima, Kenen Ohbayashi, Masaaki Nakamura, Hisayasu Terao, Makoto Uchino and Hiroaki Okabe

TRANSTHYRETIN Amyloidosis (ATTR) Thr60Ala (APPALACHIAN) VARIANT: A FAMILY STUDY
Danel Cotru, Charles L. Murphy, Sulte Macy, Kristal Weaver, Maria Schell and Alan Solomon

CHANGE IN AMYLOID FORMATION PROCESS OF TRANSTHYRETIN (TTR) IN OXIDATIVE STRESS INDUCED RATS
Kazuko Hita, Yukio Ando, Katsuki Haraoka, Takahiro Tajiri, Masaaki Nakamura, Kenen Ohbayashi, Taro Yamashita, Hisayasu Terao, Kazuko Nakagawa and Takashi Ishizaki
IXth International Symposium on Amyloidosis  
July 15-21, 2001 Budapest, Hungary
Contents

5.3.10. Poster Only  
A HIGHLY POLYMORPHIC MICROSATellite REPEAT Region 1.5 KB UPSTREAM OF TRANSTHYRETIN (TTR) EXON 1: A NEW TOOL OF USE FOR TTR HAPLOTYPE STUDIES  
Daniel R. Jacobson, Shuang Zhao and Connie Kane  
354

5.3.11. Poster Only  
NEUROPHYSIOLOGICAL EVALUATION OF PERIPHERAL NERVE FUNCTION AFTER LIVER TRANSPLANTATION IN PATIENTS WITH FAP  
Hiroshi Morita, Sachio Kobayashi, Teruko Asawa, Yo-ichi Takei, Takeshi Hattori, Takao Hashimoto and Shu-ichi Ikeda  
355

5.3.12. Poster Only  
OCULO-OPTIC MENINGEAL AMYLOIDOSIS BEFORE AND AFTER LIVER TRANSPLANTATION IN PATIENTS WITH FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP) ATTR V114C  
Masaki Nakamura, Yukio Ando, Katsuki Haraoka, Hisayasu Terazaki, Taro Yamashita, Keren Obayashi, Tetsuya Hirano and Makoto Uchino  
358

5.3.13. Poster Only  
EVALUATION OF GASTRIC FUNCTION BY ELECTROGASTROGRAM IN PATIENTS WITH FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP)  
Koren Obayashi, Yukio Ando, Masaki Nakamura, Hisayasu Terazaki, Katsuki Haraoka, Taro Yamashita and Makoto Uchino  
360

5.3.14. Poster Only  
AMYLOID FORMATION IN RAT TRANSTHYRETIN (TTR)  
Takahiro Tajiri, Yukio Ando, Kanako Hata, Kaeko Kamide, Motonori Hashimoto, Masaki Nakamura, Hisayasu Terazaki, Hirofumi Kaki, Katsuki Haraoka, Akira Isamato, Keiko Kasai, Kazuo Takechi, Kazuko Nakagawa, Hiroshi Okabe and Kazushi Ishizaki  
362

5.3.15. Poster Only  
COMPARISON OF SURAL NERVE FINDINGS BEFORE AND AFTER LIVER TRANSPLANTATION IN FAP PATIENTS  
Yo-ichi Takei, Takeshi Hattori and Shu-ichi Ikeda  
365

5.3.16. Poster Only  
PRESENCE OF VARIANT TRANSTHYRETIN IN AQUEOUS HUMOR OF PATIENTS WITH FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP ATTR VAL30MET) AFTER LIVER TRANSPLANTATION  
Yutaka Tanouchi, Katsuki Haraoka, Yukio Ando, Kanako Hata, Xuguo Sun, Masaki Nakamura, Takahiro Tajiri, Moler Erdene, Kazuko Nakagawa and Takashi Ishizaki  
367

5.3.17. Poster Only  
HEREDITARY RENAL AMYLOIDOSIS CAUSED BY A NEW VARIANT LYSOZYME W64R IN A FRENCH FAMILY  
Sophie Valleeix, Severine Drumat, Jean-Baptiste Pihlai, Dominique Adoue, Jean-Charles Piette, Dominique Droz, Brigitte Mac Gregor, Denis Canet, Marc Delpech and Gilles Grateau  
369

5.3.18. Poster Only  
RAPIDLY PROGRESSIVE AMYLOID NEUROPATHY ASSOCIATED WITH A NOVEL TRANSTHYRETIN MUTATION (Ala25Ser)  
Kamran Hamidi Ase, Masahide Yazaki, Taro Yamashita, John C Kincade, Raymond G Auger, Peter J Dyck, John R Scott and Merrill D. Berson  
372


GELSOlIN-RELATED AMYLOIDOSIS: CLINICAL MANIFESTATIONS, MUTATIONS AND MECHANISMS OF FIBRILLOGENESIS  
C.P.J. Maury  
374
IXth International Symposium on Amyloidosis
July 15-21, 2001 Budapest, Hungary
Contents

6.1.1. Poster and Oral Presentation
PROCESSING OF AMYLOIDOSIS-ASSOCIATED FORM OF GELSOLIN
Hannele Kangas and Tiina Paunio

Keynote Lecture: 6.2.

CLINICAL AND PATHOLOGICAL HETEROGENEITY IN FAP
Sho-ichi Ikeda

7. Senile Amyloidosis

Keynote Lecture: 7.1.

SENILE SYSTEMIC AMYLOIDOSIS – AN OVERVIEW
Per Westermark and Joakim Bergström

7.1.1. Poster and Oral Presentation
SENILE INTERSTITIAL PITUITARY AMYLOID: ADVANCED GLYCATION END PRODUCTS IMPORTANT FOR ITS PATHOGENESIS?
W. Saeger, M. Schwian and C. Rücken

7.1.2. Poster Only
DISTRIBUTION OF MEDIN-AMYLOID IN AGING AND IN ASSOCIATION WITH ARTERIAL DISEASES
Siwei Peng, Gunilla T. Westermark¹, Knut Sletten², Johanna Glennert and Per Westermark

7.1.3. Poster Only
PARADOXICAL ECHOCARDIOGRAPHIC AND CLINICAL FINDINGS IN SENILE VERSUS PRIMARY AMYLOIDOSIS: AN INSIGHT INTO THE MECHANISM OF CARDIOMYOPATHY
Belinda Ng, Ravin Davidoff, Martha Skinner and Rodney H Falk

8. Organ-limited Amyloidosis

Keynote Lecture: 8.1.

LOCALISED AMYLOID ASSOCIATED WITH SPECIFIC DISEASES – PATHOGENICALLY IMPORTANT?
Per Westermark

8.1.1. Poster and Oral Presentation
LACTOFERRIN AMYLOIDOSIS IN THE CORNEA
Kiyoshi Haraoka, Masaki Nakamura, Hirofumi Kai, Hisayasu Terasaki, Taro Yamashita and Yukio Ando

8.1.2. Poster and Oral Presentation
DESIGN OF PEPTIDE-BASED INHIBITORS OF HUMAN ISLET AMYLOID POLYPEPTIDE (IAPP) FIBRILLOGENESIS.
L.A. Scrooch, Y. Chen, S. Wasnuch and P.E. Fraser

8.1.3. Poster and Oral Presentation
AMYLOID AND THE PATHOGENESIS OF TYPE 2 DIABETES: INTRACELLULAR HUMAN IAPP AMYLOIDOSIS, ENDOPLASMIC RETICULAR STRESS RESPONSES AND APOPTOSIS
Henry J. Hiddinga, Setsuna Sakagashira and Norman L. Eberhardt
8.1.4. Poster and Oral Presentation
EFFECTS OF FREE FATTY ACIDS (FFAs) ON POLYMERIZATION OF ISLET AMYLOID POLYPEPTIDE (IAPP)
Gunilla T. Westermark and Zhi Ma
406

8.1.5. Poster and Oral Presentation
THE NATURE OF THE LOCALISED MENISCUS AMYLOID
J. Makovitzky
409

8.1.6. Poster Only
ANALYSIS OF AQUEOUS HUMOR PROTEINS OF EYES WITH AND WITHOUT PSEUDOEXFOLIATION SYNDROME
Jens Berlau, Josef Makovitzky, Peter Lorenz, Ria Beck, Ursula Schlöter-Schreiber, Hans-Jürgen Thiesen and Rudolf Gubisch
412

8.1.7. Poster Only
LOCALIZED AMYLOIDOSIS IN BASAL CELL CARCINOMA
Halakan Cingil
414

8.1.8. Poster Only
ORGAN-LIMITED ISOLATED BETA-2-MICROGLOBULIN AMYLOIDOSIS LOCALIZED TO THE KIDNEY
Miklos Belly and Agnes Apáthy
416

8.1.9. Poster Only
THE SPECTRUM OF CUTANEOUS AMYLOIDOSIS
Alison O. Moon, Kenneth T. Calama, Maria Balabanova and John S. Walsh
419

8.1.10. Poster Only
A NOVEL AMYLOID PROTEIN IN A CALCIFYING EPITHELIAL ODONTOGENIC (PINDBORG) TUMOR
Charles L. Murphy, Rudi Hrackic, Teresa K. Williams, Deborah T. Weiss and Alan Solomon
422

8.1.11. Poster Only
DIFFERENCES IN DISTRIBUTION OF INSULIN AND IAPP ON THE CELLULAR LEVEL
Johan Paulsson and Gunilla T. Westermark
424

8.1.12. Poster Only
CYTOTOXICITY OF HUMAN ISLET AMYLOID POLYPEPTIDE TO β-CELLS AND ISLETS IN VITRO IS REDUCED BY VITAMIN E
Ana Seghal, Claire E. Higham, Cathy Sloan and Anne Clark
427

8.1.13. Poster Only
Amyloidomas of Soft Tissue and Bone: Mayo Clinic Experience
430

9. Central Nervous System - Cerebrovascular Amyloidoses

Keynote Lecture 9.1.

EXAMINING THE MOLECULAR STRUCTURE OF ALZHEIMER'S AMYLOID-β PROTEIN
Louise C. Serpell, Johanne McLaurin, Christopher M. Yip, Margaret Sunde and Paul E. Fraser
433
IXth International Symposium on Amyloidosis
July 15-21, 2001 Budapest, Hungary
Contents

9.1.1. Poster and Oral Presentation
DOXYCYCLINE-REGULATED PRRP EXPRESSION MODULATES DEVELOPMENT OF PRION DISEASE IN TRANSGENIC MICE.
Patrick Tremblay, Katarzyna Kociuba, Jiri Safar, Stephen J. DeArmond and Stanley B. Prusiner 438

9.1.2. Poster and Oral Presentation
DETERMINATION OF POTENTIAL DIAGNOSTIC BIOMARKERS FOR ONSET OF ALZHEIMER’S DISEASE: ROLE OF ON-LINE CHROMATOGRAPHY-MASS SPECTROMETRY
Nigel J. Clarke, Frank Crow, Kenneth L. Johnson, Steven G. Younkin and Stephen Naylor 439

9.1.3. Poster and Oral Presentation
MODULATION OF A FIBRILLOGENESIS ON THE BILAYER SURFACE
J. McLaurin and C.M. Yip 442

9.1.4. Poster and Oral Presentation
CEREBROVASCULAR AMYLOIDOSIS MAY CAUSE A DECREASE OF BLOOD SUPPLY LEADING TO OXIDATIVE DAMAGE AND FORMATION OF AMYLOID PLAQUES IN THE AGING CANINE BRAIN
Jaime E. Roffina, Nikolaos Papaioannou, Irene van Andel, AnneMarie van Ederen, Marike Goossens, Marjolein Secrèvè, Ieze van der Meer, Mathilda J.M. Toussaint, Maarten Terlou and Erik Gruys 445

9.1.5. Poster Only
CYSTATIN C IMMUNOREACTIVITY IN TISSUES OUTSIDE THE CENTRAL NERVOUS SYSTEM
H. Blöndal and E. Benedikz 448

9.1.6. Poster Only
IN VITRO CYTOTOXICITY ASSAY FOR SCREENING POTENTIAL THERAPEUTICS FOR CEREBRAL AMYLOID ANGIOPATHY DISORDER
C. Morissette, V. Caouzas and F. Gervais 451

9.1.7. Poster and Oral Presentation
STEREOSELECTIVE PEPTIDE INHIBITORS OF AMYLOID-(1-40) ASSEMBLY
Robert J. Chahbou, Louis Lavone, Céline Morissette, Marie Boulé, Richard W. McLaughlin, Philippe Sarazin, Dino Stac and Francine Gervais 454

9.1.8. Poster and Oral Presentation
CHARACTERIZATION OF A MODEL OF hAPP TRANSGENIC MICE: AMYLOID DEPOSITION AND INFLAMMATION IN THE BRAIN
S. Diatal, P. Krzywowski, S. Kupicki, J. Paquette, C. Morissette and F. Gervais 457

9.1.9. Poster Only
AN AB-DEGRADING SERINE PROTEASE ACTIVITY SECRETED BY SKNMC CELLS OVEREXRESSING METALLOENDOPEPTIDASE EC 3.4.24.15
Gabriel Guidos, Rina Yaman, Franchef Siet, Michelle Lubomia, William E. Van Nostrand and Carmela R. Abraham 460

9.1.10. Poster Only
HETEROGENEITY OF AMYLOID PLAQUES IN HUMAN PRION DISEASES
Kovács GG, Havas L, László L and Mátéényi C 461

9.1.11. Poster Only
PRELIMINARY INQUIRY TO ASSESS BEHAVIOR CHANGES IN AGING PET DOGS
Jaime E. Roffina, Ieze van der Meer, Marike Goossens, Marijolein Secrèvè, Anne Marie van Ederen, Matthijs Schilder and Erik Gruys 464

9.1.12. Poster Only
DEGENERATION OF CULTURED HUMAN CEREBROVASCULAR SMOOTH MUSCLE CELLS BY CYSTATIN C EXTRACTED FROM CYSTATIN C AMYLOID
F.R. Thornodsson, D.Th. Vilhjálmsson, I.H. Olafsson and H. Blöndal 467

XV
10. Clinicopathology of Amyloidosis

Keynote Lecture: 10.1.

PHENOTYPES AND FIBRIL TYPES IN SYSTEMIC AMYLOIDOSIS
P N Hawkins

10.1.1. Poster and Oral Presentation
IS LYSOZYME VARIANT THR70ASN AMYLOIDOGENIC?
D R Booth, V Bellotti, P Mangione, S Booth, M Sunde, L C Seppel, C V Robinson, M B Pepys and P N Hawkins

10.1.2. Poster and Oral Presentation
DESCRIPTION OF A CASE OF MYELOMA NEPHROPATHY WITH PROXIMAL TUBULAR EPITHELIAL CELLS DEPOSITION OF \& LIGHT CHAIN IN FORM OF CRYSTALS AND CASTS
Marco Di Girolamo, Giovanni Selvaggi, Paizia Arcidiaco, Monica Stoppini, Giampaolo Merlini and Vittorio Bellotti

10.1.3. Poster and Oral Presentation
HEREDITARY SYSTEMIC AMYLOIDOSIS DUE TO VARIANT FIBRINOGEN A ALPHA-CHAIN IS UNEXPECTEDLY FREQUENT IN THE BRITISH POPULATION
H J Luchmann, D R Booth, S E Booth, A Bybee, J A Gilbertson, J D Gillmore and P N Hawkins

10.1.4. Poster and Oral Presentation
LIVER TRANSPLANTATION FOR END STAGE HEPATIC AMYLOIDOSIS

11. Diagnosis of Amyloidosis

Keynote Lecture: 11.1.

PRECISE DIAGNOSIS OF THE VARIOUS AMYLOID DISEASES AND NEW DEVELOPMENTS
Reinhold P Linke

11.1.1. Poster and Oral Presentation
UTILITY OF SUBCUTANEOUS FAT ASPIRATE FOR THE DIAGNOSIS OF AMYLOIDOSIS IN THE EVALUATION OF PATIENTS WITH ISOLATED PERIPHERAL NEUROPATHY
Tricia R Andrews, Gerardo Colon-Otero, Marie A Gerz, David M Menke, Kenneth T Calamia, Kevin B Boylan and Robert A Kyle

11.1.2. Poster and Oral Presentation
ABDOMINAL FAT TISSUE ASPIRATE FOR DIAGNOSIS OF AMYLOIDOSIS-10 YEAR EXPERIENCE
Caryn A Libbey, Lawrene H Connors, Niall Swan and Martha Skinner

11.1.3. Poster and Oral Presentation
AA AMYLOIDOSIS IN EGYPTIAN PATIENTS WITH LONGSTANDING RHEUMATOID ARTHRITIS

XVI
11.1.4. Poster and Oral Presentation

ANALYSIS OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAINS IN PRIMARY SYSTEMIC AMYLOIDOSIS AND LIGHT CHAIN DEPOSITION DISEASE BY NEPHELOMETRY.
Roshini S. Abraham, Jerry A. Katzmann, Raynell J. Clark, Angela Daspensieri, John Lust, A. R. Bradwell and Robert A. Kyle

11.1.5. Poster and Oral Presentation

FAMILIAL TRANSTHYRETIN AMYLOIDOSIS (ATTR): RECENT BOSTON EXPERIENCE
Lawrence Beller Connera, Amareteh Lim, Tatiana Prokaseva, Maxence Metayer, Catherine E. Costello and Martha Skinner

11.1.6. Poster Only

AMYLOID-LIKE NON-AMYLOID FIBRILLARY GLomerulopathy
P. Degrell, E. Ladhany, L. Pajar and J. Nagy

11.1.7. Poster Only

APPLICATION OF CONGO RED AND CONGO RED FLUORESCENCE TO FAT ASPIRATION BIOPSIES (FAB) AND CORRELATION TO ORGAN BIOPSIES IN DIAGNOSING SYSTEMIC AMYLOIDOSIS
Ugo Domini, Harumut Michels and Reinhold P. Linke

11.1.8. Poster Only

RETROSPECTIVE IMMUNOHISTOCHEMICAL REVIEW OF PATIENTS DIAGNOSED WITH SYSTEMIC AMYLOIDOSIS IN A SINGLE BRITISH GENERAL HOSPITAL BETWEEN 1990 AND 2000

11.1.9. Poster Only

A COMPARISON OF ECG AND ECHOCARDIOGRAPHIC FINDINGS IN 500 PATIENTS ATTENDING AN AMYLOIDOSIS CLINIC
J. Joshi, H.J. Lachmann, R. Morris and P.N. Hawkins

11.1.10. Poster Only

THE CHRONOLOGICAL SEQUENCE OF (AA) AMYLOID DEPOSITION IN VARIOUS TISSUE STRUCTURES OF THE KIDNEY IN RHEUMATOID ARTHRITIS
Judith Rabin, P. Kapp and M. Bely

11.1.11. Poster Only

IDENTIFICATION OF AMYLOID DEPOSITS BY HISTOCHEMICAL METHODS OF ROMHÁNYI AND WRIGHT: A COMPARATIVE HISTOCHEMICAL AND IMMUNOHISTOCHEMICAL STUDY
Icsa Kapolt, Icsa Petyt, Eva Balogh, Judit Bajusz, Emese Balontay and Miklós I. Bely

11.1.12. Poster Only

ULTRASTRUCTURAL LABELING IN THE DIAGNOSIS OF AMYLOIDOSIS IN RENAL BIOPSIES
Etha A. Turhat-Herrera and Guillermo A. Herrera

11.1.13. Poster Only

SYSTEMIC AMYLOIDOSIS PRESENTING AS A PERIHEPATIC MASS: ENDOSCOPIC ULTRASOUND ASSISTANCE IN DIAGNOSIS
Timothy Woodward, Michael Peco and Mauro Raimondo

Keynote Lecture 11.2.

10 YEARS EXPERIENCE WITH SERUM AMYLOID P COMPONENT SCINTIGRAPHY
P.N. Hawkins
11.2.1. Poster and Oral Presentation  
**EXTRAVASCULAR RETENTION OF SERUM AMYLOID P COMPONENT (SAP) AFTER 48 HOURS AND SEMI-QUANTITATIVE ASSESSMENT OF AMYLOID IN FAT SMEARS OF PATIENTS WITH AMYLOIDOSIS**  

11.2.2. Poster and Oral Presentation  
**TE99m-DPD SCINTIGRAPHY IN FAMILIAL AMYLOID POLYNEUROPATHY OF TRANSTHYRETIN ORIGIN**  
Max Pucil, Klaus Althard, Reinhold P. Linke, Mary K. Steen-Müller, Riguebert Kletz, Dagmar Steiner and Richard Bauer 541

**Keynote Lecture 11.3.**

**THE IMPACT OF NUCLEAR MEDICINE PROCEDURES ON THE DIAGNOSIS AND FOLLOW-UP OF AMYLOIDOSIS**  
Jörg Spitz and Luiz S. Freudenberg 544

11.3.1. Poster and Oral Presentation  
**ACCURACY OF 99mTe-APROTININ SCINTIGRAPHY IN THE DETECTION OF MYOCARDIAL AMYLOIDOSIS: LONG-TERM FOLLOW-UP OF 78 PATIENTS**  
Giampaolo Merlino, Giovanni Palladini, Vittorio Perfetti, Laura Oberti, Ernesto Anesi, Raffaella Saponaro, Giorgio Campanari and Carlo Aprile 549

11.3.2. Poster and Oral Presentation  
**POTENTIAL OF POSITRON EMISSION TOMOGRAPHY FOR NON-INVASIVE AND QUANTITATIVE IMAGING OF AMYLOIDOSIS**  
Frank Rösch 552

11.3.3. Poster and Oral Presentation  
**IMAGING OF DIALYSIS-RELATED AMYLOID (AB-AMYLOID) DEPOSITS WITH RADIOLABELED MICROGLOBULIN**  

---

**Romhányi Memorial Lectures**

12.1.  
**A GREAT HUNGARIAN PERSONALITY: PROFESSOR ROMHÁNYI THE ENTHUSIASTIC TEACHER AND MENTOR OF THOUSANDS**  
Arpad Gögi and Kinga Karlinger 555

12.2.  
**IDENTIFICATION OF AMYLOID DEPOSITS BY HISTOCHEMICAL METHODS OF ROMHÁNYI: APPLIED HISTOCHEMISTRY. SYSTEMIC SECONDARY (AA) AMYLOIDOSIS IN RHEUMATOID ARTHRITIS**  
Miklós Bely and Agnes Apathy 560

---

XVIII
13. Mini Symposium Sponsored by Neurochem

13.1. A MUTATION IN A8 ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY AND DEMENTIA
G. William Rebeck, Thomas J. Grabowski, Hyun Soon Cho, Jerry P. Melleher, William E. Van Nostrand and Steven M. Greenberg 567

13.2. MICROVASCULAR DEGENERATION AND CEREBRAL AMYLOID ANGIOPATHY IN LATE-ONSET DEMENTIA
Raj N. Kalaria 571

13.3. DEVELOPING TRANSGENIC MODELS OF CNS AMYLOID DEPOSITION
Paul E. Fraser, Peter St George-Hyslop and David Westaway 574

13.4. ANATOMICAL AND MOLECULAR FACTORS PROMOTING A-BETA DEPOSITION IN THE CEREBROVASCULAR AMYLOIDOSIS OF ALZHEIMER DISEASE
Alex E. Rotter 577

13.5. INHIBITORS OF AMYLOID DEPOSITION IN CAA
F. Gervais 578

14. Mini Symposium Sponsored by ProteoTech

14.1. Plenary Lecture
PROTEOGLYANS/GLYCOAMINOGLYCANS IN THE INDUCTION OF ALZHEIMER'S AMYLOID PLAQUE FORMATION AND THE DISCOVERY OF NATURAL ANTI-AMYLOID AGENTS
Alan D. Snow, Paula Y. Choi, Joel A. Cummings, Daniel A. Kirschner, Ann G. Yee, Steve Wood and Gerardo M. Castillo 580

14.2. PROTEOGLYCANS IN AA AMYLOIDOSIS
Robert Kisilevsky and John B. Anesin 581

14.3. AGRIN AND MICROVASCULAR DAMAGE IN ALZHEIMER'S DISEASE
Tyler M. Berezin, Brian D. Zipser, Michael S. Rafii, Rosemarie Tavares, David J. Glass, Justin R. Fallon and Edward G. Stoppa 582

14.4. SULFATED GLYCOAMINOGLYCANS AND MATRIX MOLECULES IN THE PATHOGENESIS AND TREATMENT OF AMYLOIDOSIS IN ALZHEIMER'S DISEASE
Gerardo M. Castillo, Paula Y. Choi, Joel A. Cummings and Alan D. Snow 588

14.5. GAG MIMETICS: ADVANCE IN MULTIPLE THERAPEUTIC AREAS
F. Gervais, R. Chalifour, X. Kong, C. Morissette and J. Paquette 589

XIX
# IXth International Symposium on Amyloidosis
**July 15-21, 2001 Budapest, Hungary**

## Contents

| Author’s Index (Alphabetic) | 503 |

---

XX